How to Choose Cannabis Products by Chemistry, Not Strain Name

For people considering cannabis for medical purposes, the most important information is usually not the product’s name. Labels such as “indica,” “sativa,” “hybrid,” and familiar cultivar names may offer clues about a product’s identity, but they do not reliably predict its chemical composition or effects. Cannabinoid concentrations, terpene content, product quality, dose, route of administration, and individual biology are more useful considerations.

What “strain” means—and why the term can mislead

In the cannabis industry, “strain” is commonly used to describe a cultivated variety, although cultivar is the more precise botanical term. Breeders create cultivars by selecting plants with particular characteristics and crossing them over multiple generations. Backcrossing can help preserve a desired trait, such as a certain aroma, flowering pattern, or cannabinoid profile.

Those breeding practices do not, however, make strain names standardized. The same name can be used for plants with substantially different genetics and chemistry. A study published in Nature Plants analyzed cannabis samples using genetic and chemical data and found that “sativa” and “indica” labels poorly captured overall variation. Samples with the same cultivar name could also be genetically and chemically distant from one another.

Names such as “Tangie,” “Orange Cookies,” or “Afghan Kush” may refer to aroma, reported lineage, branding, or tradition. They should not be treated as guarantees of a particular medical effect. Even products sold under the same name can differ because of genetics, growing conditions, harvest timing, storage, extraction methods, and batch-to-batch variation.

Read the cannabinoid and terpene profile

THC and CBD are the best-known cannabinoids. THC is primarily responsible for cannabis’s intoxicating effects, while CBD is not intoxicating in the same way and can influence the effects of THC and other compounds. Products may also contain smaller amounts of cannabinoids such as CBG, CBC, THCV, or acidic cannabinoids, although the clinical significance of many of these compounds remains uncertain.

Terpenes are aromatic compounds that contribute to a product’s smell and flavor. Myrcene, limonene, linalool, pinene, and beta-caryophyllene are among the terpenes frequently found in cannabis. Laboratory and animal research suggests that some terpenes may have biological activity, but the presence of a terpene does not establish that a product will produce a predictable clinical effect in a person.

The often-promoted “entourage effect”—the idea that cannabinoids and terpenes reliably work better together than in isolation—remains an active research question. Reviews have found that evidence for a stable, predictable clinical effect is limited, and laboratory studies have not established a simple explanation for how terpenes alter THC or CBD activity. Terpene data may still help consumers compare products, particularly aroma and sensory experience, but it should not be presented as a proven treatment guide.

What the evidence supports

Evidence for cannabis and cannabinoid medicines varies by condition and product. The National Academies of Sciences, Engineering, and Medicine’s evidence review found substantial or conclusive evidence for modest benefits in adults with chronic pain, chemotherapy-induced nausea and vomiting, and patient-reported spasticity related to multiple sclerosis. For many other conditions—including anxiety, depression, insomnia, and post-traumatic stress disorder—the evidence was more limited, mixed, or insufficient.

These findings do not show that a particular commercial cultivar will treat one of those conditions. Most clinical studies evaluated defined cannabinoid medicines or specific preparations rather than the full range of products sold in dispensaries. Results therefore cannot automatically be transferred from one formulation, dose, or route of administration to another.

Claims that a named cultivar is specifically suited to arthritis, fibromyalgia, depression, PTSD, creativity, or social activity should be treated cautiously. Individual responses can vary considerably, and effects may include unwanted anxiety, impaired attention, dizziness, sedation, rapid heartbeat, or intoxication.

Route of administration changes the experience

How cannabis is consumed affects how quickly effects begin, how long they last, and how much of a cannabinoid reaches the bloodstream. Inhaled THC generally acts within minutes, while edible products can take considerably longer to produce noticeable effects and may last for several hours.

A review of cannabis pharmacokinetics reports estimated inhaled THC bioavailability of roughly 10% to 35% and oral THC bioavailability of about 4% to 12%. These are broad ranges, not guarantees. Inhalation is affected by temperature, inhalation technique, device design, and material lost during combustion. Oral absorption is especially variable and can be influenced by the formulation and whether it is taken with food. A systematic review of oral cannabis and THC concluded that oral formulations have highly variable pharmacokinetic profiles.

Because edible effects are delayed, taking additional doses too soon can lead to unexpectedly intense and prolonged intoxication. Smoking also exposes the lungs to combustion products, while vaping is not risk-free and depends on the device and ingredients used. Tinctures, capsules, edibles, and inhaled products should not be assumed to be interchangeable simply because they contain similar amounts of THC or CBD.

A more reliable way to compare products

• Start with the laboratory profile: Check THC, CBD, and—when available—minor cannabinoids and terpene concentrations.
• Compare batches, not only names: Look for a certificate of analysis or other testing information that identifies potency and possible contaminants.
• Consider the route: Inhaled, oral, and sublingual products differ in onset, duration, and absorption.
• Use the lowest effective amount: Especially with THC-containing products, begin cautiously and allow enough time for the product to take effect before considering more.
• Track the response: Record dose, timing, symptom changes, side effects, sleep, and other medicines or substances used.
• Ask a qualified clinician or pharmacist: Professional guidance is particularly important for people who are pregnant or breastfeeding, have a history of psychosis or cardiovascular disease, or take medicines that may interact with cannabinoids.

In the United States, the U.S. Food and Drug Administration has not approved cannabis itself to treat any disease or condition. It has approved specific prescription products, including purified CBD and medicines containing dronabinol or nabilone, for particular indications. Many dispensary products have not undergone the FDA’s review for safety, effectiveness, consistency, or manufacturing quality.

Cannabis cultivars can differ meaningfully in chemistry and sensory qualities, but their names are an unreliable substitute for measured product information. For medical use, the strongest approach is to focus on a product’s verified cannabinoid profile, route, dose, and documented effects—while recognizing that research on terpene interactions and personalized cannabis therapy is still developing.